Chapter 2 - The Ghost in the Patent Office**
The next morning, the gray autumn sunlight filtered through the floor-to-ceiling glass windows of our penthouse apartment in downtown Chicago. The loft was immaculate, minimalist, and suffocatingly quiet. Tristan hadn't come home until past 3:00 AM, slipping into bed with practiced quietness, smelling faintly of expensive perfume and hotel soap. I had lay awake beside him in the dark, staring at the ceiling, listening to his steady breathing, feeling like a stranger sharing a bed with a ghost.
By 7:00 AM, he was already dressed in a fresh workout polo, drinking a protein shake at the kitchen island while reviewing quarterly projections on his tablet.
“Morning, babe,” he said smoothly, not even looking up from his screen. “Rough night last night. That investor dinner went late. Sorry I had to bail out early to drop Tessa off, but the poor kid was having a full-scale panic attack from the sensory overload. You understand, right?”
I stood by the coffee maker, watching the dark liquid drip slowly into the glass carafe. My voice, when I spoke, was completely level.
“Of course, Tristan. Her health is important.”
He glanced up then, a flicker of mild surprise crossing his features, as if he had braced himself for a lingering argument about last night and was relieved by my passive compliance. He flashed his signature, million-dollar CEO smile—the one that had charmed venture capitalists and bridal magazines alike.
“You’re the best, Zoe. Only thirty days until the wedding. I know things have been crazy with the Series B closing, but once we get past the ceremony in Napa, we’ll take a real vacation. Just you and me.”
*Just you and me.*
I took a sip of my black coffee, keeping my expression neutral. “Yeah. Just us.”
He grabbed his leather briefcase, kissed the top of my head with perfunctory lightness, and strode out the door, calling back over his shoulder that he had an early meeting with our corporate patent attorneys to finalize the intellectual property transfer agreements for the new lab expansion.
The moment the front door clicked shut, I set my coffee mug down.
I didn't go to the office. Instead, I walked into my home study, unlocked the bottom drawer of my mahogany desk, and pulled out a heavy, fireproof lockbox. Inside sat the physical paper trail of my entire adult life.
People in the tech industry looked at Apex Biotech and saw Tristan Vance. They saw the charismatic frontman on the cover of Forbes, the smooth talker who wore tailored suits and spoke eloquently about curing genetic disorders. But nobody looked at the fine print of the original founding documents signed seven years ago when we were broke graduate students at Northwestern University.
Back then, Tristan had charm, ambition, and a silver tongue, but he couldn't pass a basic organic chemistry exam to save his life. I was the one who spent three years isolating the synthetic antibody sequence in a cramped, poorly ventilated academic lab. I was the one who filed the initial provisional patents.
And when we incorporated Apex Biotech, Tristan had insisted on structuring the company with himself as the majority voting shareholder and CEO, convincing me that keeping our assets unified under his corporate umbrella would make us look more stable to institutional investors. Naive, exhausted, and deeply in love, I had agreed, signing over the operational management rights while retaining my position as Chief Scientific Officer.
What Tristan had conveniently forgotten—or perhaps never fully understood because he never bothered to read the complex legal clauses drafted by my uncle, a retired federal IP attorney—was the reversionary clause embedded in Patent Portfolio 7-B.
The clause stated quite clearly: All core intellectual property rights, synthetic sequences, and molecular formulations assigned to Apex Biotech remain exclusively contingent upon the active, unencumbered marital union or formal co-ownership of the primary inventor, Dr. Zoe Hastings. In the event of a contractual breach, moral turpitude, or dissolution of the foundational partnership prior to commercialization, 100% of the patent rights automatically revert back to the primary inventor with zero corporate buyout liability.
In plain English?
If Tristan broke our engagement due to infidelity, or if our partnership dissolved before the final commercial rollout scheduled for next month, he didn't just lose a fiancée.
He lost the entire biochemical foundation of Apex Biotech. Without my patents, the company was legally reduced to an empty shell holding a pile of rented lab equipment and a mountain of debt.
I pulled out my phone and dialed a direct, unlisted number.
“Hello, Marcus?” I said when the line picked up on the second ring.
Marcus, our senior corporate counsel and my old college roommate, answered with a guarded tone. “Zoe? Hey. Is everything okay? Tristan’s been breathing down my neck all morning about getting the final IP assignment signatures notarized before the wedding.”
May you like
“Everything is better than okay,” I replied, a cold, sharp smile touching my lips. “Marcus, I need you to pull up the original 2019 incorporation agreement and turn to Schedule C, Paragraph Four. We need to have a little chat about what happens when a CEO breaches his fiduciary and personal contracts thirty days before walking down the aisle.”
---
